Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Interest Receivables (2018 - 2025)

Historic Change in Interest Receivables for Marker Therapeutics (MRKR) over the last 8 years, with Q3 2025 value amounting to -$9182.0.

  • Marker Therapeutics' Change in Interest Receivables rose 9947.4% to -$9182.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $920743.0, marking a year-over-year increase of 3927.5%. This contributed to the annual value of $1.3 million for FY2024, which is 19597.57% up from last year.
  • Marker Therapeutics' Change in Interest Receivables amounted to -$9182.0 in Q3 2025, which was up 9947.4% from -$784430.0 recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Change in Interest Receivables registered a high of $1.6 million during Q4 2024, and its lowest value of -$1.7 million during Q3 2024.
  • Over the past 5 years, Marker Therapeutics' median Change in Interest Receivables value was $1948.0 (recorded in 2022), while the average stood at $34978.6.
  • As far as peak fluctuations go, Marker Therapeutics' Change in Interest Receivables skyrocketed by 1201651666.67% in 2022, and later tumbled by 6781652.98% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Change in Interest Receivables stood at -$6.0 in 2021, then skyrocketed by 12016516.67% to $720985.0 in 2022, then surged by 31.0% to $944502.0 in 2023, then surged by 69.64% to $1.6 million in 2024, then crashed by 100.57% to -$9182.0 in 2025.
  • Its last three reported values are -$9182.0 in Q3 2025, -$784430.0 for Q2 2025, and $112062.0 during Q1 2025.